Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.

Lin H, Yamashita DS, Zeng J, Xie R, Wang W, Nidarmarthy S, Luengo JI, Rhodes N, Knick VB, Choudhry AE, Lai Z, Minthorn EA, Strum SL, Wood ER, Elkins PA, Concha NO, Heerding DA.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):673-8. doi: 10.1016/j.bmcl.2009.11.064. Epub 2009 Nov 20.

PMID:
20006497
2.

Discovery of thiophene inhibitors of polo-like kinase.

Emmitte KA, Andrews CW, Badiang JG, Davis-Ward RG, Dickson HD, Drewry DH, Emerson HK, Epperly AH, Hassler DF, Knick VB, Kuntz KW, Lansing TJ, Linn JA, Mook RA Jr, Nailor KE, Salovich JM, Spehar GM, Cheung M.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21. doi: 10.1016/j.bmcl.2008.11.041. Epub 2008 Nov 18.

PMID:
19097784
3.

Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors.

Stevens KL, Reno MJ, Alberti JB, Price DJ, Kane-Carson LS, Knick VB, Shewchuk LM, Hassell AM, Veal JM, Davis ST, Griffin RJ, Peel MR.

Bioorg Med Chem Lett. 2008 Nov 1;18(21):5758-62. doi: 10.1016/j.bmcl.2008.09.069. Epub 2008 Sep 24.

PMID:
18835709
4.

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.

Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, Li M, Safonov IG, Takata DT, Venslavsky JW, Yamashita DS, Choudhry AE, Copeland RA, Lai Z, Schaber MD, Tummino PJ, Strum SL, Wood ER, Duckett DR, Eberwein D, Knick VB, Lansing TJ, McConnell RT, Zhang S, Minthorn EA, Concha NO, Warren GL, Kumar R.

J Med Chem. 2008 Sep 25;51(18):5663-79. doi: 10.1021/jm8004527.

PMID:
18800763
5.

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.

Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN 3rd, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA.

J Med Chem. 2008 Aug 14;51(15):4632-40. doi: 10.1021/jm800566m. Epub 2008 Jul 12.

PMID:
18620382
6.

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.

Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R.

Cancer Res. 2008 Apr 1;68(7):2366-74. doi: 10.1158/0008-5472.CAN-07-5783.

7.

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M.

Mol Cancer Ther. 2007 Jul;6(7):2012-21.

8.

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA Jr, Cheung M.

Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31.

9.

Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.

Sammond DM, Nailor KE, Veal JM, Nolte RT, Wang L, Knick VB, Rudolph SK, Truesdale AT, Nartey EN, Stafford JA, Kumar R, Cheung M.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3519-23.

PMID:
15990302
10.

Retraction.

Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT Jr, Grifffen RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk-Chapman L, Veal JM, Walker DH, Kuyper LF.

Science. 2002 Dec 20;298(5602):2327. No abstract available.

PMID:
12526115
11.

Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.

Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT Jr, Griffin RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk L, Veal JM, Walker DH, Kuyper LF.

Science. 2001 Jan 5;291(5501):134-7. Retraction in: Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT Jr, Grifffen RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk-.

12.

Clinical experience with leucovorin and 5-fluorouracil.

Laufman LR, Brenckman WD Jr, Stydnicki KA, Morgan ED, Collier M, Knick VB, Duch DS, Mullin R, Ferone R.

Cancer. 1989 Mar 15;63(6 Suppl):1031-5.

PMID:
2783880
13.

Clinical experience with CF-FUra.

Laufman LR, Brenckman WD Jr, Stydnicki KA, Morgan ED, Collier M, Knick VB, Duch DS, Mullin R, Ferone R.

Adv Exp Med Biol. 1988;244:201-11.

PMID:
3073655
14.

Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U).

Elwell LP, Ferone R, Freeman GA, Fyfe JA, Hill JA, Ray PH, Richards CA, Singer SC, Knick VB, Rideout JL, et al.

Antimicrob Agents Chemother. 1987 Feb;31(2):274-80.

15.

Supplemental Content

Loading ...
Support Center